National EQ-5 D tariffs and quality-adjusted life-year estimation : comparison of UK , US and Danish utilities in south Swedish rheumatoid arthritis patients

[1]  Anthony O'Hagan,et al.  A comparison of United States and United Kingdom EQ‐5D health states valuations using a nonparametric Bayesian method , 2010, Statistics in medicine.

[2]  T. Kvien,et al.  Comparison of utility measures and their relationship with other health status measures in 1041 patients with rheumatoid arthritis , 2010, Annals of the rheumatic diseases.

[3]  C. Gudex,et al.  Generation of a Danish TTO value set for EQ-5D health states , 2009, Scandinavian journal of public health.

[4]  Jeffrey A. Johnson,et al.  A Comparison of EQ-5D Index Scores Derived from the US and UK Population-Based Scoring Functions , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  R. Holloway,et al.  The Implications of Using US-Specific EQ-5D Preference Weights for Cost-Effectiveness Evaluation , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.

[6]  P. Stalmeier,et al.  The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. , 2006, Health economics.

[7]  W. Greiner,et al.  Validating the EQ-5D with time trade off for the German population , 2005, The European Journal of Health Economics.

[8]  M. Sculpher,et al.  Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. , 2005, Health economics.

[9]  Stephen Joel Coons,et al.  US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.

[10]  Nan Luo,et al.  Valuations of EQ-5D Health States: Are the United States and United Kingdom Different? , 2005, Medical care.

[11]  J. Fries,et al.  Measuring effectiveness of drugs in observational databanks: promises and perils , 2004, Arthritis research & therapy.

[12]  P. Geborek,et al.  Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden , 2002, Annals of the rheumatic diseases.

[13]  P. Kind,et al.  A Comparison of United Kingdom and Spanish General Population Time Trade-off Values for EQ-5D Health States , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[14]  D. Osoba,et al.  Measuring health-related quality of life. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[16]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.

[17]  P. Dolan,et al.  The time trade-off method: results from a general population study. , 1996, Health economics.

[18]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .